NO20053773L - Parentale peptidformuleringer for behandling av systemisk lupus erytematosus - Google Patents
Parentale peptidformuleringer for behandling av systemisk lupus erytematosusInfo
- Publication number
- NO20053773L NO20053773L NO20053773A NO20053773A NO20053773L NO 20053773 L NO20053773 L NO 20053773L NO 20053773 A NO20053773 A NO 20053773A NO 20053773 A NO20053773 A NO 20053773A NO 20053773 L NO20053773 L NO 20053773L
- Authority
- NO
- Norway
- Prior art keywords
- amino acids
- sequence
- peptide
- composition
- systemic lupus
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 230000003172 anti-dna Effects 0.000 abstract 2
- 239000008365 aqueous carrier Substances 0.000 abstract 2
- 239000008137 solubility enhancer Substances 0.000 abstract 2
- 241000699670 Mus sp. Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rehabilitation Therapy (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Sammendrag Den foreliggende oppfinnelsen tilveiebringer en farmasøytisk sammensetning som omfatter: en vandig bærer; fra 0, 1 mg/ml til 20 mg/ml av sammensetningen av et farmasøytisk akseptabelt salt av a) peptid som omfatter minst 12 og mest 30 etterfølgende aminosyrer som har en sekvens som korresponderer til (i) en sekvens av aminosyrer som finnes innen en komplementaritetsbestemmende region (CDR) fra en tung eller en lett kjede fra et humant monoklonalt anti-DNA 16/6 Id antistoff, eller (ii) en sekvens med aminosyrer som finnes innen en komplementaritetsbestemmende region (CDR) til en tung eller en lett kjede fra et patogent anti-DNA monoklonalt antistoff som induserer en systemisk lupus erytematøs (SLE) lignende sykdomsrespons hos mus, eller b) et peptid som onifatter etterfølgende aminosyrer som har sekvensen som er vist ved en hver av SEQ ID nr. 8-17, eller c) et peptid som omfatter etterfølgende aminosyrer som har en sekvens fra en hver av (a) og (b) eller som har minst to av sekvensene i (a)(1), (a)(ii) og (b)(i) til (b)(x), eller d) et peptid som omfatter etterfølgende aminosyrer som har en sekvens som omfatter minst to identiske sekvenser som er indusert i (a)(i), (a)(ii) og (b)(i) til (b)(x); og oppløselighetsforsterker hvor både peptidet og oppløselighetsforsterkeren blir løst i den vandige bæreren; og hvor sammensetningen har en pH mellom 4 og 9 og en fremgangsmåte for å forbedre symptomer av SLE i et menneske ved å gi en effektiv mengde av sammensetningen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43991803P | 2003-01-14 | 2003-01-14 | |
| PCT/US2004/000948 WO2004064787A2 (en) | 2003-01-14 | 2004-01-14 | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20053773D0 NO20053773D0 (no) | 2005-08-08 |
| NO20053773L true NO20053773L (no) | 2005-10-12 |
Family
ID=32771757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20053773A NO20053773L (no) | 2003-01-14 | 2005-08-08 | Parentale peptidformuleringer for behandling av systemisk lupus erytematosus |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20050008634A1 (no) |
| EP (1) | EP1594434B1 (no) |
| JP (2) | JP4817068B2 (no) |
| KR (1) | KR20050100617A (no) |
| CN (1) | CN1774259B (no) |
| AU (1) | AU2004206842A1 (no) |
| BR (1) | BRPI0406745A (no) |
| CA (1) | CA2513320C (no) |
| CO (1) | CO5640143A2 (no) |
| CR (1) | CR7938A (no) |
| DK (1) | DK1594434T3 (no) |
| EA (1) | EA009123B1 (no) |
| EC (1) | ECSP055961A (no) |
| ES (1) | ES2606464T3 (no) |
| IL (1) | IL169574A (no) |
| IS (1) | IS7972A (no) |
| MX (1) | MXPA05007549A (no) |
| NO (1) | NO20053773L (no) |
| NZ (1) | NZ541658A (no) |
| WO (1) | WO2004064787A2 (no) |
| ZA (1) | ZA200506206B (no) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL141647A0 (en) * | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| UA83816C2 (ru) * | 2003-01-14 | 2008-08-26 | Тева Фармасьютикал Индастриз, Лтд | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ СОДЕРЖИТ ПЕПТИД И ЗАМЕЩЕННЫЙ β-ЦИКЛОДЕКСТРИН, ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКИ |
| EP1594434B1 (en) * | 2003-01-14 | 2016-09-07 | Yeda Research and Development Co. | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| CN102281903B (zh) * | 2008-11-17 | 2013-11-13 | 弗·哈夫曼-拉罗切有限公司 | 降低大分子在生理条件下聚集的方法和配方 |
| DK3702374T3 (da) | 2012-02-15 | 2022-06-27 | Cydex Pharmaceuticals Inc | Fremsgangsmåde til fremstilling for cyclodextrin-derivater |
| EA201590199A1 (ru) * | 2012-07-12 | 2015-05-29 | Санофи | Противоопухолевая композиция, содержащая соединение 1-(6-{[6-(4-фторфенил)[1,2,4]триазоло[4,3-b]пиридазин-3-ил]сульфанил}-1,3-бензотиазол-2-ил)-3-(2-морфолин-4-илэтил)мочевины |
| WO2014066274A1 (en) | 2012-10-22 | 2014-05-01 | Cydex Pharmaceuticals, Inc. | Alkylated cyclodextrin compositions and processes for preparing and using the same |
| WO2014193611A1 (en) * | 2013-05-29 | 2014-12-04 | Oklahoma Medical Research Foundation | Bright/arid3a function/expression as a marker for systemic lupus erythematosus severity and intensity |
| WO2015013669A1 (en) | 2013-07-26 | 2015-01-29 | The Regents Of The University Of California | Mps peptides and use thereof |
| US10314889B2 (en) * | 2013-12-20 | 2019-06-11 | The Regents Of The University Of California | Suppression of allergic lung inflammation and hyperreactivity |
| JP6914188B2 (ja) | 2014-08-22 | 2021-08-04 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | 分画アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法 |
| HRP20250951T1 (hr) | 2015-12-30 | 2025-10-10 | F. Hoffmann-La Roche Ag | Formulacije sa smanjenom razgradnjom polisorbata |
| JOP20170017B1 (ar) | 2016-01-25 | 2021-08-17 | Amgen Res Munich Gmbh | تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص |
| US11167005B2 (en) | 2017-01-05 | 2021-11-09 | Yeda Research And Development Co. Ltd. | Peptides for treating Sjogren's syndrome |
| WO2018186343A1 (ja) * | 2017-04-04 | 2018-10-11 | 日東電工株式会社 | 凍結乾燥体の製造方法及びその製造装置 |
| US10975121B2 (en) | 2017-06-24 | 2021-04-13 | Cytogel Pharma, Llc | Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof |
| AU2018375087B2 (en) * | 2017-11-30 | 2023-10-05 | Cytogel Pharma, Llc | Novel analgesic pharmaceutical formulations and uses thereof |
| CN112143707A (zh) * | 2020-09-29 | 2020-12-29 | 广东先康达生物科技有限公司 | 一种治疗自身免疫细胞的免疫细胞及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60184098A (ja) * | 1984-03-02 | 1985-09-19 | Suntory Ltd | 新規なペプチド及びこれを有効成分とする利尿剤 |
| US6407079B1 (en) * | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US5126249A (en) * | 1989-05-09 | 1992-06-30 | Eli Lilly And Company | Enzymatic removal of a protein amino-terminal sequence |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9200247D0 (en) * | 1992-01-07 | 1992-02-26 | Erba Carlo Spa | Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation |
| US5646131A (en) * | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
| US6613536B1 (en) * | 1995-03-28 | 2003-09-02 | Yeda Research And Development Co. Ltd. | Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| IL113159A0 (en) * | 1995-03-28 | 1995-06-29 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
| IL120503A0 (en) * | 1997-03-20 | 1997-07-13 | Hadasit Med Res Service | Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them |
| US20020054872A1 (en) * | 1997-03-20 | 2002-05-09 | Yaakov Naparstek | Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus |
| SE9802938D0 (sv) * | 1998-09-01 | 1998-09-01 | Astra Ab | Improved stability for injection solutions |
| IL141647A0 (en) * | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| UA83816C2 (ru) * | 2003-01-14 | 2008-08-26 | Тева Фармасьютикал Индастриз, Лтд | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ СОДЕРЖИТ ПЕПТИД И ЗАМЕЩЕННЫЙ β-ЦИКЛОДЕКСТРИН, ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКИ |
| EP1594434B1 (en) * | 2003-01-14 | 2016-09-07 | Yeda Research and Development Co. | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
| US7018891B2 (en) * | 2003-12-16 | 2006-03-28 | International Business Machines Corporation | Ultra-thin Si channel CMOS with improved series resistance |
-
2004
- 2004-01-14 EP EP04702215.7A patent/EP1594434B1/en not_active Expired - Lifetime
- 2004-01-14 CN CN2004800069872A patent/CN1774259B/zh not_active Expired - Lifetime
- 2004-01-14 BR BR0406745-2A patent/BRPI0406745A/pt not_active IP Right Cessation
- 2004-01-14 AU AU2004206842A patent/AU2004206842A1/en not_active Abandoned
- 2004-01-14 US US10/758,397 patent/US20050008634A1/en not_active Abandoned
- 2004-01-14 NZ NZ541658A patent/NZ541658A/en unknown
- 2004-01-14 ES ES04702215.7T patent/ES2606464T3/es not_active Expired - Lifetime
- 2004-01-14 KR KR1020057013098A patent/KR20050100617A/ko not_active Withdrawn
- 2004-01-14 WO PCT/US2004/000948 patent/WO2004064787A2/en not_active Ceased
- 2004-01-14 DK DK04702215.7T patent/DK1594434T3/da active
- 2004-01-14 JP JP2006500956A patent/JP4817068B2/ja not_active Expired - Fee Related
- 2004-01-14 CA CA2513320A patent/CA2513320C/en not_active Expired - Lifetime
- 2004-01-14 EA EA200501131A patent/EA009123B1/ru not_active IP Right Cessation
- 2004-01-14 MX MXPA05007549A patent/MXPA05007549A/es not_active Application Discontinuation
-
2005
- 2005-07-06 IL IL169574A patent/IL169574A/en active IP Right Grant
- 2005-08-03 ZA ZA200506206A patent/ZA200506206B/en unknown
- 2005-08-05 IS IS7972A patent/IS7972A/is unknown
- 2005-08-08 NO NO20053773A patent/NO20053773L/no not_active Application Discontinuation
- 2005-08-09 CR CR7938A patent/CR7938A/es not_active Application Discontinuation
- 2005-08-10 CO CO05079328A patent/CO5640143A2/es not_active Application Discontinuation
- 2005-08-11 EC EC2005005961A patent/ECSP055961A/es unknown
-
2008
- 2008-11-10 US US12/291,439 patent/US20090169559A1/en not_active Abandoned
-
2011
- 2011-03-24 JP JP2011066343A patent/JP2011173888A/ja active Pending
-
2012
- 2012-04-23 US US13/453,979 patent/US20130023485A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CR7938A (es) | 2006-05-31 |
| MXPA05007549A (es) | 2006-05-19 |
| EP1594434A4 (en) | 2008-09-10 |
| IS7972A (is) | 2006-07-15 |
| IL169574A0 (en) | 2007-07-04 |
| CA2513320A1 (en) | 2004-08-05 |
| WO2004064787A3 (en) | 2005-12-15 |
| ECSP055961A (es) | 2006-04-19 |
| IL169574A (en) | 2015-08-31 |
| JP2011173888A (ja) | 2011-09-08 |
| NO20053773D0 (no) | 2005-08-08 |
| US20130023485A1 (en) | 2013-01-24 |
| CO5640143A2 (es) | 2006-05-31 |
| JP4817068B2 (ja) | 2011-11-16 |
| JP2006517540A (ja) | 2006-07-27 |
| DK1594434T3 (da) | 2017-01-02 |
| CN1774259A (zh) | 2006-05-17 |
| CN1774259B (zh) | 2011-12-28 |
| WO2004064787A2 (en) | 2004-08-05 |
| BRPI0406745A (pt) | 2005-12-20 |
| ZA200506206B (en) | 2006-12-27 |
| ES2606464T3 (es) | 2017-03-24 |
| KR20050100617A (ko) | 2005-10-19 |
| EA200501131A1 (ru) | 2006-04-28 |
| EP1594434A2 (en) | 2005-11-16 |
| EP1594434B1 (en) | 2016-09-07 |
| NZ541658A (en) | 2008-04-30 |
| EA009123B1 (ru) | 2007-10-26 |
| CA2513320C (en) | 2018-03-27 |
| US20090169559A1 (en) | 2009-07-02 |
| US20050008634A1 (en) | 2005-01-13 |
| AU2004206842A1 (en) | 2004-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20053773L (no) | Parentale peptidformuleringer for behandling av systemisk lupus erytematosus | |
| JP7664158B2 (ja) | トランスフェリン受容体標的ペプチド | |
| ES2566830T3 (es) | Péptido capaz de extender la semivida de péptido de interés en plasma | |
| CN101815724B (zh) | 用于将轭合至其的试剂递送至组织的抑肽酶样多肽 | |
| Chorev | The partial retro–inverso modification: A road traveled together | |
| ES2404940T3 (es) | Reactivos de peptoide específicos para prión | |
| WO2004024090A3 (en) | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence | |
| NO20045021L (no) | Immunologiske metoder og preparater for behandling av Alzheimers sykdom | |
| EA200400289A1 (ru) | Производные аминоизоксазола, активные в качестве ингибиторов киназы | |
| CY1107051T1 (el) | Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους | |
| CN109891245A (zh) | 自身免疫疾病的诊断、预防和/或治疗 | |
| NO20063026L (no) | Antistoffer | |
| US20230330238A1 (en) | Chimeric conjugates for degradation of viral and host proteins and methods of use | |
| US20160083455A1 (en) | Antiviral agent against animal viruses | |
| JP2006506942A5 (no) | ||
| NO331277B1 (no) | Farmasoytisk sammensetning omfattende polypetid/nukleinsyre for behandling av retinale degenererende sykdommer, vektor, isolert polypeptid, renset antistoff og anvendelse av polypeptid, nukleinsyre og antistoff, samt fremgangsmater og kit | |
| WO2017192594A1 (en) | Binding moieties for biofilm remediation | |
| DK1417222T3 (da) | Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop | |
| JP2001103993A (ja) | 環状ペプチド及びセリンプロテアーゼ阻害剤 | |
| EA200501129A1 (ru) | Парентеральные композиции пептида для лечения системной красной волчанки | |
| EP1615610A2 (en) | Inhibitors of coronavirus | |
| CN102159231A (zh) | 治疗免疫介导的登革热感染和登革热感染(包括登革出血热和登革休克综合征)的抗体依赖性增强作用的方法 | |
| RU2005126236A (ru) | Фьюжн-белок для подавления цервикального рака | |
| RU2007115411A (ru) | Пептиды hsp60 и их apl-производные и фармацевтические композиции | |
| Silva et al. | Synthetic angiotensin II peptide derivatives confer protection against cerebral and severe non-cerebral malaria in murine models |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |